Insulin as Therapeutic Agent against Alzheimer's Disease

Daniela Giacomazza[1]* and Marta Di Carlo[2]

[1]Consiglio Nazionale delle Ricerche–Istituto di Biofisica, Via U. La Malfa 153–90146, Palermo, Italy
[2]Consiglio Nazionale delle Ricerche–Istituto di Biomedicina e Immunologia Molecolare, Via U. La Malfa 153–90146 Palermo, Italy

Alzheimer's Disease (AD) is the most common form of dementia in the elderly and it is clinically characterized by gradual worsening of the symptoms. Patients affected by AD have, at the initial stage of the pathology, mild memory loss, difficulty performing routine tasks, trouble communicating and understanding written material. At the final stage of the disease they lose the ability to feed themselves, speak, recognize people and a constant care is typically necessary.

At microscopic level AD is characterized by neuronal cell loss and increasing deposition of Neurofibrillary Tangles (NTF) inside the cells and formation of amyloid plaques in the spaces among neurons and in the walls of blood vessels [1].

NTF are insoluble twisted fibers consisting primarily of the Tau protein, which, in physiological conditions, forms the microtubules. In Alzheimer's disease, however, Tau is chemically changed and the microtubule structures collapse.

Amyloid plaques are mainly composed by the amyloid beta peptide (A-beta), a 39-to-43 peptide originating from the sequential enzymatic cleavage of the larger trans-membrane protein called Amyloid Precursor Protein (APP). Accumulation of A-beta is hypothesized to trigger the pathogenic cascade leading to AD [2] and in the last decade, many observations confirm that small A-beta oligomers, (also called A-beta-Derived Diffusible Ligands (ADDLs)) instead of large fibril aggregates, are the most dangerous and toxic species in the AD onset [3,4]. Their accumulation and binding in the proximity of synapses causes oxidative stress, loss of spines and receptors critical for neuron plasticity and memory [5].

On the basis of the large number of observations, since the first years of the XXI century it has been suggested a close tie between AD and disorder in insulin signaling, in particular the insulin resistance associated to diabetes type 2 [6-10] so that AD is recognized as a neuroendocrine disorder and it has been defined as a type of "diabetes type 3" or "brain diabetes" [11,12].

It has been reported [13] that insulin can protect cultured rat neurons against A-beta induced toxicity. Experimental data [14] have demonstrated that A-beta competes for binding of insulin to its receptor. This results in a decrease in the autophosphorylation of the insulin receptor. Other studies indicate that insulin, interacting with A-beta, inhibits its fibrillar growth, as shown in a cell-free assay and in the cell surface of human brain pericytes, reducing the A-beta toxic effect [15]. Recently, it has been proposed that physiological insulin and pathological ADDLs are capable to regulate their mutual binding site abundance, creating a competitive balance between synapse survival and degeneration. The decline of the insulin signaling in the brain with the age displaces this delicate equilibrium in favor of the ADDLs [5]; thus, the use of new drugs recovering this balance could be a promising therapeutic strategy.

On these starting points, what is, at molecular level, the effect of insulin against A-beta toxicity? Some evidences indicate that insulin can recover the cell viability by inhibition of intrinsic apoptotic program, involving caspase 9 and 3 activation [10]. Moreover, insulin prevents mitochondrial dysfunction by inhibition of the Reactive Oxygen Species (ROS) formation and activation of specific cell signaling. Insulin activates the serine-threonine kinase Akt, a protein involved in survival pathway, suggesting that insulin signaling provides a physiological defense mechanism to contrast the death program triggered by A-beta oligomers [16,17].

Akt phosphorylation needs activation or inhibition of several proteins involved in the apoptotic signaling cascade such as the Bcl-2 protein family. Furthermore, insulin promotes its survival program by shuttling of Akt in different sub-cellular compartments [18]. Translocation of Akt from the cytoplasm to the nucleus, induces negative regulation of gene expressions via Foxo3a, a pro-apoptotic transcription factor. Akt translocation from the cytoplasm to the mitochondrion mediates, instead, the protection of this organelle through phosphorylation of Bad and probably HK-II, two proteins involved in cell death. Thus, the same molecule, depending on its phosphorylated or unphosphorylated state, can be present in different cellular compartments such as nucleus, cytoplasm and mitochondrion and this localization is essential to determine whether the cell will live or die. Therefore, a precise balance between signals promoting survival and apoptosis is important for determining cell fate [18]. Because insulin signaling in the brain is known to decline with age the result of this balance represents a risk factor for AD well suited for therapeutic intervention with the same insulin.

In the last few years many attempts have been done to slow or stop the AD progression with the aid of insulin but the usual method used to treat diabetes could be very dangerous for AD patients and for this reason alternative routes of administration have been explored.

The intranasal administration of insulin, already tested for diabetes treatment, to AD patients has improved delayed memory. Changes in memory and function were associated with changes in the A-beta 42 level and in the Tau protein–to-A-beta 42 ratio in cerebrospinal fluid [19]. Unfortunately, together with positive effects this method presents contraindications such as irritation and damage of the nasal mucosa [20] and, surely more important, increase of the systolic, diastolic and mean arterial blood pressures [21].

The improvement of delivery systems capable to overcome the blood brain barrier and deliver the insulin straight in the brain could be a promising route to avoid unpleasant side effects.

*Corresponding author: Daniela Giacomazza, Consiglio Nazionale delle Ricerche–Istituto di Biofisica, Via U. La Malfa 153–90146, Palermo, Italy, E-mail: daniela.giacomazza@cnr.it

References

1. Wisniewski HM, Frackowiak J (1998) Differences between the pathogenesis of senile plaques and congophilic angiopathy in Alzheimer disease. J Neuropathol Exp Neurol 57: 96-98.

2. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388.

3. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453.

4. Picone P, Carrotta R, Montana G, Nobile MR, San Biagio PL, et al. (2009) Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys J 96: 4200-4211.

5. De Felice FG, Vieira MNN, Bomfim TR, Decker H, Velasco PT, et al. (2009) Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 106: 1971-1976.

6. Rönnemaa E, Zethelius B, Sundelöf J, Sundström J, Degerman-Gunnarsson M, et al. (2008) Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 71: 1065-1071.

7. Hoyer S (2002) The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 109: 341-360.

8. Hoyer S (2004) Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol 541: 135-152.

9. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, et al. (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8: 247-268.

10. Di Carlo M, Picone P, Carrotta R, Giacomazza D, San Biagio PL (2010) Insulin promotes survival of amyloid-beta oligomers neuroblastoma damaged cells via caspase 9 inhibition and Hsp70 upregulation. J Biomed Biotechnol.

11. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, et al. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes? J Alzheimers Dis 7: 63-80.

12. de la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 7: 45-61.

13. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, et al. (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22: 246-260.

14. Carrotta R, Di Carlo M, Manno M, Montana G, Picone P, et al. (2006) Toxicity of recombinant beta-amyloid prefibrillar oligomers on the morphogenesis of the sea urchin Paracentrotus lividus. FASEB J 20: 1916-1917.

15. Rensink AA, Otte-Holler I, de Boer R, Bosch RR, ten Donkelaar HJ, et al. (2004) Insulin inhibits amyloid beta- induced cell death in cultured human brain pericytes. Neurobiol Aging 25: 93-103.

16. Song G, Ouyang G, Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71.

17. Lee H-K, Kumar P, Fu Q, Rosen KM, Querfurth HW (2009) The insulin/Akt signaling pathway is targeted by intracellular beta amyloid. Mol Biol Cell 20: 1533-1544.

18. Picone P, Giacomazza D, Vetri V, Carrotta R, Militello V, et al. (2011) Insulin-activated Akt rescues Aβ oxidative stress-induced cell death by orchestrating molecular trafficking. Aging Cell 10: 832-843.

19. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, et al. (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69: 29-38.

20. Nolte MS, Taboga C, Salamon E, Moses A, Longenecker J, et al. (1990) Biological activity of nasally administered insulin in normal subjects. Horm Metab Res 22: 170-174.

21. Cernea S, Raz I (2006) Intranasal insulin: PK profile designed specifically for prandial treatment of Type 2 Diabetes. Drugs Today 42: 405-424.